+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tissue Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 111 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5617198
UP TO OFF until Dec 31st 2023
The global tissue microarray market is expected to register a CAGR of more than 10% during the forecast period, 2022-2027.

The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the tissue microarray market. The COVID-19 pandemic has turned a spotlight on the molecular diagnostics industry across the world, with the rapid development of diagnostics, fast-tracked regulatory clearances, and ramped-up distribution in various regions to help curb the spread of the virus. For instance, as per a January 2022 published article titled, "Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans", tissue microarrays incorporating a total of 879 tissue cores from conjunctival (n = 84), sinonasal (n = 95), and lung (bronchiolar/alveolar; n = 96) specimens were investigated for protein expression by immunohistochemistry. The study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract. Such studies indicate significant demand for tissue microarray products amid the pandemic. Also, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to witness positive growth in the coming period.

The growth of the market can be attributed to the factors such as research and development in drug discovery, the rising burden of cancer, and increasing demand for accurate methods.

The rising prevalence of cancer is driving the demand for tissue microarray products. For instance, according to the World Health Organization (WHO), cancer accounted for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths due to the growth and aging of the population, apart from other factors, such as smoking, poor diet, physical inactivity, and fewer childbirths. The tissue diagnostics capture the disease insights and the parameters that factor into the patient outcomes. Additionally, according to GLOBOCAN 2020, the estimated number of new cases of breast cancer cases in 2020 was 2.26 million, and the number is estimated to reach 3.19 million by the year 2040. Thus, the demand for tissue microarrays is increasing owing to the growing burden of cancer.

Additionally, strategic initiatives taken by market players are also propelling the growth of the market. For instance, in March 2021, Oxford BioDynamics Plc and Agilent Technologies signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch Explorer Array Kit.

However, the availability of alternative technologies and the high cost associated with microarray techniques are the factors hindering the market growth.

Key Market Trends

Immunohistochemistry Segment is Expected to Hold a Major Market Share in the Tissue Microarray Market

By procedure, the immunohistochemistry segment is expected to hold a major share in the market. Immunohistochemistry is one of the most common applications of immunostaining. It involves the process of selectively identifying antigens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues.

The major factors fueling the market growth are the increasing application of immunohistochemistry in tissue diagnostics as well as the growing research and development.

For instance, as per a September 2019 published article titled, "Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues", to assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different types and 608 normal tissues were analyzed at two different antibody concentrations. The study concluded that prostate-specific antigen (PSA) immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.

Additionally, the launch of new products is also propelling the growth of the market. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit. It is the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens. Such launches also boost the growth of the market segment.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

Within North America, the United States has held a major share of the market. The major factors contributing to the market growth are the presence of many market players engaged in manufacturing and expanding the portfolio of instruments and reagents for molecular diagnostic testing. The region also witnesses the presence of well-established healthcare diagnostic facilities.

For instance, as per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020, and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer, with 284,200 cases. These factors are leading to an increased demand for DNA repair drugs in the region.

In addition, as per a 2020 report by the American Cancer Society, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines.

Several market players are also engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in July 2021, BioIVT, one of the leading providers of research models and services for drug and diagnostic development, acquired Tissue Solutions Ltd. Tissue Solutions provides medical researchers with high-quality human tissue and other biological materials for use in drug discovery, target identification and validation, assay development and validation, and biomarker and companion diagnostic development.

Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.

Competitive Landscape

The tissue microarray market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Novus Biologicals, OriGene Technologies, Inc, ProteoGenex, PREMIER Biosoft, and BioIVT, among other players.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Research and Development in Drug Discovery
4.2.2 Rising Burden of Cancer
4.2.3 Increasing Demand For Accurate Diagnostic Methods
4.3 Market Restraints
4.3.1 Availability of Alternative Techniques
4.3.2 High Cost Associated With Microarray Techniques
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value- USD million)
5.1 By Procedure
5.1.1 Immunohistochemistry
5.1.2 Fluorescence in situ hybridization (FISH)
5.1.3 In Situ Hybridization
5.1.4 Other Procedure Types
5.2 By Technology
5.2.1 Polymerase Chain Reaction (PCR)
5.2.2 Next-Generation Sequencing
5.2.3 DNA Microarray
5.2.4 Other Technology Types
5.3 By End User
5.3.1 Pharmaceutical and Biotechnological Companies
5.3.2 Research Organizations
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Novus Biologicals
6.1.2 ProteoGenex
6.1.3 PREMIER Biosoft
6.1.4 OriGene
6.1.5 Biocompare
6.1.6 BioIVT
6.1.7 US Biolab
6.1.8 Arrayit Corporation
6.1.9 Protein Biotechnologies
6.1.10 Applied Microarrays
6.1.11 BioCat GmbH
6.1.12 Bio SB
6.1.13 Creative Bioarray
6.1.14 Abcam
6.1.15 Auria Biobank

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novus Biologicals
  • ProteoGenex
  • PREMIER Biosoft
  • OriGene
  • Biocompare
  • BioIVT
  • US Biolab
  • Arrayit Corporation
  • Protein Biotechnologies
  • Applied Microarrays
  • BioCat GmbH
  • Bio SB
  • Creative Bioarray
  • Abcam
  • Auria Biobank